Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2025)

Bicycle Therapeutics' Cash & Equivalents history spans 8 years, with the latest figure at $628.1 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 28.58% year-over-year to $628.1 million; the TTM value through Dec 2025 reached $628.1 million, down 28.58%, while the annual FY2025 figure was $628.1 million, 28.58% down from the prior year.
  • Cash & Equivalents reached $628.1 million in Q4 2025 per BCYC's latest filing, down from $648.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $961.4 million in Q2 2024 to a low of $198.7 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $531.1 million, with a median of $457.0 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: surged 222.58% in 2021, then decreased 28.58% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $438.7 million in 2021, then dropped by 22.69% to $339.2 million in 2022, then surged by 55.22% to $526.4 million in 2023, then skyrocketed by 67.07% to $879.5 million in 2024, then fell by 28.58% to $628.1 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Cash & Equivalents are $628.1 million (Q4 2025), $648.3 million (Q3 2025), and $721.5 million (Q2 2025).